ClinicalTrials.gg
CompletedNCT00872534Updated Aug 11, 2015Results posted

Endoscopic Evaluation of Upper Gastrointestinal (GI) Mucosal Damage Induced by PL-2200 Versus Aspirin in Healthy Volunteers

A Phase 1/2 interventional study of acetylsalicylic acid in Upper Gastrointestinal Mucosal Damage, sponsored by PLx Pharma. Completed at 6 sites in United States. Open to participants aged 50 Years to 75 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2015-08-11.

Sponsored by PLx Pharma · Phase 1/2, Interventional, and Prevention

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
204
Allocation
Randomized
Ages
50 Years to 75 Years
Sex
All
01

Study summary

To determine the gastrointestinal safety of PL-2200 versus immediate-release aspirin by assessing endoscopic gastroduodenal mucosal injury at approved daily cardiac-protective doses of aspirin (325 mg) in normal healthy volunteers.

02

Conditions studied

  • Upper Gastrointestinal Mucosal Damage

Keywords

  • To evaluate the acute gastrointestinal safety of PL-2100.
03

In context

Lead sponsor

PLx Pharma is the lead sponsor of 11 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
50 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subject is ≥50 to ≤75 years of age.
  • Subject is healthy.
  • Subject has a between 20 and 32
  • If female and of child bearing potential, subject has a negative pregnancy test and is not nursing.

Exclusion criteria

Exclusion Criteria:

  • Subject has abnormal screening/baseline laboratory parameters or endoscopic observations deemed by the Investigator.
  • Subject has an active Helicobacter pylori infection.
  • Subject has a prior GI ulcer, bleeding, obstruction or perforation.
  • Subject has taken aspirin or any aspirin containing product within the last 4 weeks, or a non-aspirin NSAID product within 2 weeks.
  • Subject has taken any of the following medications within 2 weeks prior to enrollment: Any anti- agents, anti-coagulants or selective serotonin reuptake inhibitors.
  • Subject has used an agent within the past 30 days.
  • Subject has or to aspirin, ibuprofen, or other NSAID.
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Investigator)
Enrollment
204 participants (actual)

Study arms

  • Experimental
    PL-2200

    PL-2200 is an NSAID product containing 325mg of acetylsalicylic acid and phosphatidylcholine in a neutral lipid matrix.

    Drug: acetylsalicylic acid

  • Active comparator
    Aspirin

    Immediate release 325mg aspirin

    Drug: acetylsalicylic acid

Interventions

06

What researchers measure

Primary outcomes

  1. Incidence of Subjects With Gastroduodenal Erosions and Ulcers.

    Incidence of subjects with gastroduodenal composite scores of 3 or 4 (\> 5 erosions or 1 or more ulcers 3 mm or greater in length with unequivocal depth).

    Time frame: After 7 days of study medication

07

Results

Posted Aug 11, 2015

Participant flow

Participant flow — Overall Study
MilestonePL-2200Aspirin
Started100104
Completed97101
Not completed33

Outcome measures

PrimaryIncidence of Subjects With Gastroduodenal Erosions and Ulcers.

Incidence of subjects with gastroduodenal composite scores of 3 or 4 (\> 5 erosions or 1 or more ulcers 3 mm or greater in length with unequivocal depth).

Time frame:
After 7 days of study medication
Reported as:
Number · participants
Incidence of Subjects With Gastroduodenal Erosions and Ulcers.
participantsPL-2200Aspirin
Gastroduodenal Composite Score of 3 or 4 (NO)7254
Gastroduodenal Composite Score of 3 or 4 (YES)1936

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
PL-2200—0/100 (0%)8/100 (8%)
Aspirin—0/104 (0%)14/104 (13.5%)
Most frequent other events
Most frequent other events
EventPL-2200Aspirin
Stomach UlcerGastrointestinal disorders3/10010/104
NauseaGastrointestinal disorders5/1004/104

Baseline characteristics

Age, Continuous
Age, Continuous(years)PL-2200AspirinTotal
Mean58.1 ± 6.3556.6 ± 6.0057.3 ± 6.20
Sex: Female, Male
Sex: Female, Male(Participants)PL-2200AspirinTotal
Female444488
Male5660116
08

Study locations

6 sites
  • Jupiter Research
    Jupiter, Florida, United States
  • Miami Research Associates
    South Miami, Florida, United States
  • Oklahoma Foundation for Digestive Research
    Oklahoma City, Oklahoma, United States
  • Altoona Arthritis and Osteoporosis Center
    Altoona, Pennsylvania, United States
  • Dallas VA Medical Center
    Dallas, Texas, United States
  • Houston Center For Clinical Research
    Houston, Texas, United States
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jan 2009, a primary completion of Jul 2009 and a completion of Jul 2009. It does not say whether these dates are actual or estimated.

Results were first posted in Aug 2015, 6 years 1 month after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 10, 2009
First posted
Mar 31, 2009
Start
Jan 2009
Primary completionActual
Jul 2009
CompletionActual
Jul 2009
Results first posted
Aug 11, 2015
Last update
Aug 11, 2015
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 11, 2015, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00872534
Lead sponsor
PLx Pharma
Responsible party
Sponsor
First posted
Mar 31, 2009
Start date
Jan 2009
Primary completion
Jul 2009
Completion
Jul 2009
Results posted
Aug 11, 2015
Last update
Aug 11, 2015

Study contacts

Byron L Cryer, MD
principal investigator · Dallas VA
Frank L Lanza, MD
principal investigator · Houston Institute for Clinical Research
Michael E Schwartz, DO
principal investigator · Jupiter Research
Alan J Kivitz, MD
principal investigator · Altoona Arthritis and Osteoporosis Center
Phillip B Miner, MD
principal investigator · Oklahoma Foundation for Digestive Research
Howard Schwartz, MD
principal investigator · Miami Research Associates

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2015. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Aspirin

Start the discussion